AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06551558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: per operative warming
Description: per-operative warming only thanks to the Optimized Forced air blanket with a prewarming of 10 minutes performed in the operating room.
Study NCT05115253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA behavioural counselling + SMS text message boosters
Description: Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.
Study NCT05115253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JITAI
Description: EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
Study NCT04806451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Description: CRF1-receptor antagonist
Study NCT04806451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crinecerfont
Description: CRF1-receptor antagonist
Study NCT04806451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form
Study NCT06261814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV
Study NCT06261814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS
Study NCT06261814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE
Study NCT06261814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT05951582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercises
Description: The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone
Study NCT05951582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills
Study NCT05723146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial cognition assessment
Description: The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
Study NCT05990803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
Study NCT05990803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
Study NCT06275126 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CONSYDER decision aid
Description: Web-based breast cancer surgery decision aid
Study NCT04696549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual visual art experience guided by Visual Thinking Strategies
Description: All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
Study NCT04141696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Given intravenously over 40 minutes
Study NCT04141696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam (placebo)
Description: Given intravenously over 40 minutes
Study NCT05587881 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine(donor)
Description: Donor received COVID-19 vaccine before stem cells collection.
Study NCT05587881 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine(patient)
Description: Patient received COVID-19 vaccine before allo-HSCT.
Study NCT04697914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.
Description: to protect the metatarsus and prevent the appearance of foot pain.
Study NCT04697914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.
Description: to protect the metatarsus and prevent the appearance of foot pain.
Study NCT04381130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-009
Description: Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy
Study NCT05180253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Esophageal studies
Description: Healthy subjects will undergo esophageal and blood testing.
Study NCT05584345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. Exercises with a wand will be performed 10 times in each direction. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. The physiotherapist will perform these stretches 5 times in each direction, pausing for 20 seconds at the conclusion of each repeat. TENS will be applied for 20 minutes. In addition, a 15-minute cold pack application will be made to the shoulder region. The application of theraband strengthening exercises will depend on the patients' state.
Study NCT05584345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Exercises
Description: Diaphragmatic breathing and thoracic expansion breathing exercises will be applied 5 days a week.
Study NCT05506007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Study NCT05506007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216-R
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Study NCT05506007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216
Description: During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.
Study NCT05010018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based application connecting small food store owners and suppliers of healthier foods and beverages
Description: The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
Study NCT06432595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability resistance training and Traditional resistance training
Description: The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.
Study NCT05110963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Uniform Standard of Care Counseling
Description: Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
Study NCT05110963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Regulation Skills Counseling
Description: Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
Study NCT05110963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Self-Regulation Skills Counseling + Stigma Management
Description: Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
Study NCT06267703 — intervention group
Intervention type: OTHER
Intervention: Metabolomic profiling
Description: Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
Study NCT05862701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin
Description: 5% permethrin cream
Study NCT05862701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphur
Description: 10% Sulfur ointment
Study NCT04072471 — intervention group
Intervention type: DRUG
Intervention: Zurampic®
Description: non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
Study NCT04072471 — intervention group
Intervention type: DRUG
Intervention: Control group: xanthine oxidase inhibitor monotherapy
Description: non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
Study NCT05841576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMET monitoring device
Description: Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
Study NCT06357767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence
Description: A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
Study NCT04899206 — intervention group
Intervention type: DRUG
Intervention: With an Antidepressant Drug
Description: Current users of an antidepressant drug.
Study NCT04899206 — intervention group
Intervention type: DRUG
Intervention: Without an Antidepressant Drug
Description: Non-current users of an antidepressant drug.
Study NCT05043870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab and immunosuppressives
Description: the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
Study NCT05043870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
Study NCT04808921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test
Description: Rapid Antigen diagnostic device performance comparative to RT-PCR
Study NCT04695158 — intervention group
Intervention type: DRUG
Intervention: COVID-19 group (Group I)
Description: Routine COVID-19 treatment
Study NCT05127486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC.
Study NCT05127486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: Administered orally.
Study NCT05127486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT05127486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT04732663 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Cross-sectional study, no intervention.
Study NCT06093932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songling Xuemaikang Capsules
Description: 3 capsules at a time, three times a day, duration: 12 weeks
Study NCT06093932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: everyday, duration: 12 weeks
Study NCT06093932 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: everyday, duration: 12 weeks
Study NCT06093932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules at a time, three times a day, duration: 12 weeks
Study NCT05841628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532 nm laser treatment
Description: The port wine birthmark will be treated with the DermaV 532 nm laser.
Study NCT04776330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA targeted prime CAR-T cells
Description: BCMA targeted prime CAR-T cell therapy
Study NCT05601674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: : Conventional flow Anesthesia
Description: During the initial wash-in period 2 L/min Fresh gas flow will be used.
Study NCT05601674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Anesthesia
Description: Fresh gas flow rate will be 0.5 L/min throughout the procedure.
Study NCT05038293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated mouthpiece-based toothbrush
Description: One-time use during study visit.
Study NCT04695158 — intervention group
Intervention type: DRUG
Intervention: Type II Diabetes Mellitus and COVID-19 group (Group II)
Description: Routine Type II Diabetes Mellitus and COVID-19 treatments
Study NCT04797169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Health
Description: In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
Study NCT04797169 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Noom Digital Health
Description: In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
Study NCT05286515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Peroperative PT
Description: The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.
Study NCT05286515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Practice PT
Description: This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
Study NCT05038293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: One-time use during study visit.
Study NCT05195762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFX-179 Gel 1.50%
Description: Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi.
Study NCT06515405 — intervention group
Intervention type: DRUG
Intervention: Hydrocortisone
Description: Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023).
Study NCT05704426 — intervention group
Intervention type: DEVICE
Intervention: Impulse Dynamics Optimizer Device
Description: The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
Study NCT06559735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CereVu Device
Description: Observational, non-invasive measurements
Study NCT05364853 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person Testing
Description: Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
Study NCT05364853 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote Testing
Description: Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
Study NCT05447793 — intervention group
Intervention type: DEVICE
Intervention: Fitostimoline plus
Description: Formulation in gauzes and cream